Literature DB >> 18363036

Thrombophilias and arteriovenous fistula dysfunction in maintenance hemodialysis.

Ramazan Danis1, Sehmus Ozmen, Davut Akin, Sabri Batun, Serdar Kahvecioglu, Abdullah Altintas, Mehmet E Yilmaz, Adil Polat.   

Abstract

Most episodes of fistula thrombosis are consequences of underlying physioanatomic abnormalities. However, some dialysis access thrombosis develops independent from any obvious anatomic cause. We aimed to clarify the role of thrombophilias in primary and secondary AVF failure. One hundred eighty nine arteriovenous fistulas in 116 adults on maintenance hemodialysis were analyzed. All subjects were evaluated for many thrombotic factors. Fistula information was obtained both from the patients' self reports, and from their medical records. Twenty-seven AVFs in 18 cases (14.3%) had pAVFF. The percentage of subjects with a BMI < 20 kg/m(2) was significantly lower than no-pAVFF group (P = 0.03). ATIII levels and albumin values were significantly lower in patients with sAVFF compared to those with no sAVFF. Other parameters were similar. There was no statistically significant difference between pAFFF versus No-pAFFF and sAFFF versus No-sAFFF groups with respect to all mutant alleles count. Routine extended analyses of all thrombophillic factors are not recommended in AVFF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363036     DOI: 10.1007/s11239-008-0216-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  43 in total

1.  Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation.

Authors:  B Ataç; U Yakupoğlu; N Ozbek; F N Ozdemir; N Bilgin
Journal:  Transplant Proc       Date:  2002-09       Impact factor: 1.066

2.  Anticardiolipin antibody and Taiwanese chronic haemodialysis patients with recurrent vascular access thrombosis.

Authors:  F-R Chuang; H-W Chang; C-L Lin; I-K Wang; H-Y Chang; P-H Wang; C-C Yang; T-C Chen; C-S Wu; C-H Lee
Journal:  Int J Clin Pract       Date:  2005-07       Impact factor: 2.503

3.  Heterozygosity for factor V Leiden in a haemodialysis patient with recurrent shunt thrombosis.

Authors:  C Bremer; R M Schaefer
Journal:  Nephrol Dial Transplant       Date:  1997-08       Impact factor: 5.992

4.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

5.  Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access.

Authors:  C J LeSar; H W Merrick; M R Smith
Journal:  J Am Coll Surg       Date:  1999-07       Impact factor: 6.113

6.  Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.

Authors:  M Födinger; C Mannhalter; I Pabinger; D Koizar; C Rintelen; W H Hörl; G Sunder-Plassmann
Journal:  Nephrol Dial Transplant       Date:  1996-04       Impact factor: 5.992

7.  IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis.

Authors:  S Adler; L Szczech; A Qureshi; R Bollu; R Thomas-John
Journal:  Clin Nephrol       Date:  2001-12       Impact factor: 0.975

Review 8.  Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies.

Authors:  Robert J Kim; Richard C Becker
Journal:  Am Heart J       Date:  2003-12       Impact factor: 4.749

9.  Effect of recombinant human erythropoietin on vascular access.

Authors:  G R Dy; E J Bloom; G K Ijelu; G W Merritts; M S Kramer; R M Raja
Journal:  ASAIO Trans       Date:  1991 Jul-Sep

10.  Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis.

Authors:  Susan I O'shea; Jeffrey H Lawson; Donal Reddan; Michael Murphy; Thomas L Ortel
Journal:  J Vasc Surg       Date:  2003-09       Impact factor: 4.268

View more
  5 in total

1.  ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis.

Authors:  Danyelle R A Rios; Maria G Carvalho; Roberta C Figueiredo; Cláudia N Ferreira; Valério L Rodrigues; Regina A Souza; Ana C Simões e Silva; Ana Paula Fernandes; Karina B Gomes; Luci M S Dusse
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

2.  Plasma von Willebrand Factor and a Disintegrin and Metalloproteinase with Eight Thrombospondin-type 1 Motif Levels in Hemodialysis Patients: Relation to Vascular Access Thrombosis.

Authors:  Khaled M A Elzorkany; Belal A M Montaser; Sally M El-Hefnawy
Journal:  Indian J Nephrol       Date:  2018 Jul-Aug

3.  Thrombophilic risk factors and ABO blood group profile for arteriovenous access failure in end stage kidney disease patients: a single-center experience.

Authors:  Sunnesh Reddy Anapalli; Harini Devi N; Pvgk Sarma; Lokanathan Srikanth; Siva Kumar V
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

4.  Inherited protein S deficiency due to a novel nonsense mutation in the PROS1 gene in the patient with recurrent vascular access thrombosis: A case report.

Authors:  Eun Jin Cho; Yong Chul Kim; Jin Ho Hwang; Hajung Lee; Sung Sup Park; So Yeon Kim; Suhnggwon Kim; Ho Jun Chin
Journal:  Kidney Res Clin Pract       Date:  2012-01-18

Review 5.  A meta-analysis of the association between diabetic patients and AVF failure in dialysis.

Authors:  Yan Yan; Dan Ye; Liu Yang; Wen Ye; Dandan Zhan; Li Zhang; Jun Xiao; Yan Zeng; Qinkai Chen
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.